Hospital
Magnolia Regional Health Center
Magnolia Regional Health Center was paid $29.32M by Medicaid between Jan 2018 and Dec 2024, across 332 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoMAGNOLIA REGIONAL HEALTH CENTER
CORINTH, MS 38834
CORINTH, MS 38834
33aNPI1699756445assigned 11/09/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$29.32M
24GClaims844,275
24DCodes billed332
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#19 of 77
Median peer was paid$8.23M
This provider vs. median3.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 168,378 | $5.44M | |
| 2019 | 146,455 | $5.70M | |
| 2020 | 112,956 | $3.92M | |
| 2021 | 112,932 | $4.02M | |
| 2022 | 118,536 | $3.77M | |
| 2023 | 103,365 | $3.59M | |
| 2024incomplete | 81,653 | $2.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 21,555 | 17,656 | $3.38M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.2% | 20,612 | 17,375 | $2.71M |
| G0378 | Hospital observation service, per hour | 8.2% | 6,101 | 4,761 | $2.39M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 11,130 | 9,249 | $1.95M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 13,668 | 10,492 | $1.28M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 6,770 | 5,754 | $908K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.0% | 12,278 | 3,420 | $875K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.9% | 16,289 | 4,319 | $864K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.8% | 9,418 | 5,231 | $828K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 17,171 | 3,811 | $816K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.1% | 3,430 | 3,043 | $613K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.0% | 7,036 | 4,245 | $586K |
320 more codes
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.9% | 7,641 | $564K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.9% | 1,640 | $548K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 14,113 | $542K |
| 71046 | Radiologic examination, chest; 2 views | 1.7% | 12,437 | $498K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.6% | 4,494 | $482K |
| 93458 | 1.6% | 503 | $458K | |
| 59025 | Fetal non-stress test | 1.4% | 4,213 | $413K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 10,713 | $334K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 19,756 | $315K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 6,200 | $313K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 3,125 | $300K |
| 86885 | <1% | 4,103 | $280K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,104 | $276K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 3,674 | $272K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 10,309 | $265K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 172 | $213K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,604 | $212K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 858 | $210K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,232 | $202K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,776 | $201K |
| 80053 | Comprehensive metabolic panel | <1% | 24,482 | $180K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 339 | $171K |
| A0425 | Ground mileage, per statute mile | <1% | 5,361 | $161K |
| 86900 | <1% | 3,540 | $160K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,471 | $157K |
| 87507 | <1% | 566 | $155K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 44 | $148K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 1,763 | $138K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,245 | $128K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 25,086 | $126K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,203 | $118K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 18,223 | $113K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,116 | $110K |
| 36415 | Collection of venous blood by venipuncture | <1% | 45,846 | $100K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,355 | $99K |
| 93017 | <1% | 1,821 | $95K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,838 | $95K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,833 | $93K |
| 84484 | <1% | 13,892 | $87K | |
| 85027 | <1% | 19,689 | $80K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 12,992 | $77K |
| 62323 | <1% | 675 | $76K | |
| 74018 | <1% | 1,904 | $75K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,236 | $70K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,702 | $69K |
| 76830 | Ultrasound, transvaginal | <1% | 993 | $67K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,627 | $67K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 985 | $62K |
| 80055 | <1% | 1,611 | $58K | |
| 83880 | <1% | 3,158 | $57K | |
| 73562 | <1% | 1,586 | $56K | |
| 87800 | <1% | 1,833 | $53K | |
| 71250 | <1% | 1,571 | $50K | |
| 86901 | <1% | 3,540 | $49K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 736 | $47K |
| 87040 | <1% | 6,691 | $46K | |
| 82805 | <1% | 1,226 | $44K | |
| 73630 | <1% | 1,067 | $43K | |
| 87186 | <1% | 6,051 | $43K | |
| 97162 | <1% | 1,508 | $42K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,577 | $39K |
| 73610 | <1% | 913 | $38K | |
| 81025 | <1% | 5,830 | $37K | |
| 84702 | <1% | 3,231 | $37K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,246 | $37K |
| 80306 | <1% | 3,544 | $35K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 88 | $35K |
| 73030 | <1% | 1,042 | $35K | |
| 87481 | <1% | 460 | $33K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 973 | $32K |
| 87070 | <1% | 4,177 | $31K | |
| 87430 | <1% | 2,254 | $31K | |
| 85007 | <1% | 13,404 | $31K | |
| 96367 | <1% | 1,179 | $30K | |
| 83690 | <1% | 6,750 | $30K | |
| 87799 | <1% | 463 | $30K | |
| 80061 | Lipid panel | <1% | 3,344 | $29K |
| 81001 | <1% | 11,620 | $28K | |
| 72141 | <1% | 401 | $26K | |
| 47562 | <1% | 12 | $26K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 992 | $25K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,583 | $25K |
| 88142 | <1% | 1,705 | $25K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 661 | $25K |
| 83605 | <1% | 3,825 | $25K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 233 | $25K |
| 73130 | <1% | 615 | $24K | |
| 83735 | <1% | 7,321 | $24K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 213 | $24K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 73 | $20K |
| 85730 | <1% | 5,189 | $19K | |
| 73110 | <1% | 426 | $19K | |
| 85610 | <1% | 7,230 | $19K | |
| 73502 | <1% | 626 | $19K | |
| 82962 | <1% | 10,889 | $17K | |
| 74019 | <1% | 320 | $16K | |
| 93971 | <1% | 486 | $15K | |
| 86703 | <1% | 1,328 | $15K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,258 | $14K |
| 87590 | <1% | 913 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 742 | $14K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 190 | $13K |
| 82105 | <1% | 1,135 | $13K | |
| 87490 | <1% | 909 | $13K | |
| 81003 | <1% | 6,101 | $12K | |
| 87512 | <1% | 461 | $12K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 624 | $12K |
| 87631 | <1% | 2,615 | $11K | |
| 80076 | <1% | 1,183 | $11K | |
| 86140 | <1% | 2,600 | $11K | |
| 81000 | <1% | 4,194 | $11K | |
| C9447 | Injection, phenylephrine and ketorolac, 4 ml vial | <1% | 125 | $11K |
| 72110 | <1% | 173 | $11K | |
| 84439 | <1% | 1,251 | $10K | |
| 70486 | <1% | 186 | $10K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 66 | $10K |
| 82565 | <1% | 3,356 | $10K | |
| 29581 | <1% | 194 | $9K | |
| 86803 | <1% | 960 | $9K | |
| 87081 | <1% | 1,607 | $8K | |
| 82607 | <1% | 850 | $8K | |
| 83540 | <1% | 1,742 | $8K | |
| 97533 | <1% | 743 | $8K | |
| 83655 | <1% | 708 | $7K | |
| 36600 | <1% | 243 | $7K | |
| 85379 | <1% | 1,090 | $7K | |
| 72131 | <1% | 192 | $7K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 262 | $7K |
| 70491 | <1% | 103 | $7K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 337 | $6K |
| 82950 | <1% | 1,632 | $6K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 124 | $6K |
| 78227 | <1% | 33 | $6K | |
| 82677 | <1% | 325 | $6K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 279 | $5K |
| 82150 | <1% | 788 | $5K | |
| 36430 | <1% | 44 | $5K | |
| 86762 | <1% | 467 | $5K | |
| 83550 | <1% | 776 | $5K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 41 | $5K |
| 86592 | <1% | 1,577 | $5K | |
| 87340 | <1% | 697 | $5K | |
| 84520 | <1% | 1,340 | $5K | |
| 86922 | <1% | 62 | $4K | |
| 82728 | <1% | 534 | $4K | |
| 76642 | <1% | 130 | $4K | |
| 86336 | <1% | 322 | $4K | |
| 92526 | <1% | 69 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 64 | $4K |
| 88304 | <1% | 146 | $4K | |
| 64635 | <1% | 12 | $4K | |
| 73590 | <1% | 104 | $3K | |
| 82570 | <1% | 964 | $3K | |
| 64493 | <1% | 29 | $3K | |
| 85652 | <1% | 1,713 | $3K | |
| 84156 | <1% | 1,238 | $3K | |
| 85014 | <1% | 1,633 | $3K | |
| 76775 | <1% | 37 | $3K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 197 | $3K |
| J3490 | Unclassified drugs | <1% | 11,714 | $3K |
| 76536 | <1% | 41 | $3K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 41 | $3K |
| 87075 | <1% | 475 | $2K | |
| 82247 | <1% | 556 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 14,268 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 15,158 | $2K |
| 80074 | <1% | 37 | $2K | |
| 73080 | <1% | 38 | $2K | |
| 86704 | <1% | 204 | $2K | |
| 85018 | <1% | 943 | $2K | |
| 73090 | <1% | 44 | $2K | |
| 94060 | <1% | 14 | $2K | |
| 94726 | <1% | 14 | $2K | |
| 82746 | <1% | 203 | $2K | |
| 84132 | <1% | 503 | $2K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,082 | $2K |
| 86705 | <1% | 187 | $2K | |
| A0427 | Emergency ambulance ride, advanced life support | <1% | 2,121 | $2K |
| 86706 | <1% | 216 | $2K | |
| 31720 | <1% | 31 | $1K | |
| 12001 | <1% | 13 | $1K | |
| 83001 | <1% | 72 | $1K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 9,220 | $1K |
| 72100 | <1% | 26 | $1K | |
| 84550 | <1% | 363 | $1K | |
| 70498 | <1% | 19 | $1K | |
| 97116 | <1% | 59 | $1K | |
| 86677 | <1% | 74 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 25 | $1K |
| 82803 | <1% | 110 | $1K | |
| 82043 | <1% | 214 | $1K | |
| 93925 | <1% | 16 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,538 | $1K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 13 | $991.03 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,177 | $988.82 |
| 82274 | <1% | 92 | $949.06 | |
| 72050 | <1% | 14 | $899.59 | |
| 86038 | <1% | 91 | $896.17 | |
| 70496 | <1% | 14 | $870.12 | |
| 96376 | <1% | 3,954 | $864.52 | |
| 80143 | <1% | 88 | $842.73 | |
| 76770 | <1% | 13 | $798.91 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,426 | $735.78 |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 55 | $729.20 |
| 72081 | <1% | 12 | $712.68 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,871 | $630.28 |
| 84146 | <1% | 51 | $602.90 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,090 | $599.80 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 3,029 | $587.44 |
| J2704 | Injection, propofol, 10 mg | <1% | 8,336 | $563.35 |
| 97161 | <1% | 12 | $558.80 | |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 1,367 | $553.29 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 378 | $549.92 |
| A0429 | Emergency ambulance ride, basic life support | <1% | 1,492 | $533.60 |
| 87205 | <1% | 199 | $524.21 | |
| 82947 | <1% | 189 | $513.65 | |
| 80179 | <1% | 51 | $503.40 | |
| 82977 | <1% | 90 | $501.34 | |
| 0352U | <1% | 55 | $476.99 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,032 | $425.69 |
| 87210 | <1% | 114 | $421.06 | |
| 81015 | <1% | 169 | $420.75 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,115 | $418.48 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,039 | $389.55 |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 334 | $382.24 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,412 | $356.00 |
| 51702 | <1% | 36 | $350.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,496 | $333.80 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,596 | $309.21 |
| 87116 | <1% | 29 | $288.17 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,593 | $254.42 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,059 | $243.56 |
| 84144 | <1% | 15 | $239.98 | |
| 87102 | <1% | 29 | $224.70 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 6,119 | $223.51 |
| 82550 | <1% | 70 | $222.15 | |
| 82077 | <1% | 19 | $217.56 | |
| 99406 | <1% | 1,052 | $216.77 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 13 | $178.56 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $171.85 |
| 88174 | <1% | 14 | $159.81 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 2,584 | $150.34 |
| 83615 | <1% | 32 | $142.71 | |
| 82310 | <1% | 27 | $142.17 | |
| 94760 | <1% | 212 | $135.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 171 | $109.68 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,198 | $107.11 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 233 | $99.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 628 | $97.36 |
| 84460 | <1% | 16 | $82.05 | |
| 84450 | <1% | 16 | $80.19 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 914 | $71.22 |
| 86308 | <1% | 31 | $68.37 | |
| 82010 | <1% | 16 | $66.15 | |
| 87206 | <1% | 12 | $65.89 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,592 | $55.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 800 | $48.73 |
| 99152 | <1% | 1,315 | $43.53 | |
| 84100 | <1% | 18 | $42.70 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 199 | $40.20 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 618 | $39.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 983 | $31.00 |
| C1769 | Guide wire | <1% | 1,682 | $30.65 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 749 | $29.25 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,483 | $22.29 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 572 | $22.15 |
| 99153 | Mod sedat endo service >5yrs | <1% | 639 | $21.77 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,146 | $14.79 |
| 76937 | <1% | 47 | $14.11 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 641 | $5.28 |
| J1815 | Injection, insulin, per 5 units | <1% | 3,463 | $5.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 24 | $4.32 |
| V2632 | Posterior chamber intraocular lens | 0% | 372 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 776 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 312 | $0.00 |
| A0426 | Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) | 0% | 64 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 270 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 976 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 254 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 80 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 302 | $0.00 |
| 80050 | General health panel | 0% | 41 | $0.00 |
| 76998 | 0% | 65 | $0.00 | |
| 36591 | 0% | 46 | $0.00 | |
| 80329 | 0% | 48 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 165 | $0.00 |
| 64494 | 0% | 29 | $0.00 | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0% | 84 | $0.00 |
| G8991 | Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 37 | $0.00 |
| 96368 | 0% | 41 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 14 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 699 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 1,640 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 2,000 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 767 | $0.00 |
| 90715 | 0% | 573 | $0.00 | |
| J1245 | Injection, dipyridamole, per 10 mg | 0% | 76 | $0.00 |
| 80321 | 0% | 107 | $0.00 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 456 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 215 | $0.00 |
| J1956 | Injection, levofloxacin, 250 mg | 0% | 48 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 90 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 364 | $0.00 |
| 84145 | 0% | 129 | $0.00 | |
| 64495 | 0% | 27 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 80 | $0.00 |
| 64636 | 0% | 26 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 47 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 30 | $0.00 |
| 84112 | 0% | 82 | $0.00 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 13 | $0.00 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | 0% | 35 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 63 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 82 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 81 | $0.00 |
| 76942 | 0% | 16 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 21 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 15 | $0.00 |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 33 | $0.00 |
| 94729 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOBSON, JAMES (CEO)
| Provider | Location | Paid |
|---|---|---|
| Magnolia Regional Health Center | Corinth, MS | $7.49M |
| Magnolia Regional Health Center | Corinth, MS | $2.04M |
| Magnolia Ambulance Services | Corinth, MS | $1.36M |
| Magnolia Regional Health Center | Corinth, MS | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.